Huntington National Bank’s Krystal Biotech KRYS Stock Holding History

Huntington National Bank’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.3K	Sell	183 -5	-3%	-$1.33K	﹤0.01%	1359
2025 Q4	$46.3K	Sell	188 -2	-1%	-$421	﹤0.01%	1275
2025 Q3	$33.5K	Sell	190 -66	-26%	-$9.88K	﹤0.01%	1423
2025 Q2	$35.2K	Buy	256 +43	+20%	+$6.32K	﹤0.01%	1363
2025 Q1	$38.4K	Sell	213 -366	-63%	-$61.6K	﹤0.01%	1293
2024 Q4	$90.7K	Buy	579 +6	+1%	+$1.06K	﹤0.01%	970
2024 Q3	$104K	Buy	573 +283	+98%	+$54.6K	﹤0.01%	894
2024 Q2	$53.3K	Buy	290 +47	+19%	+$7.89K	﹤0.01%	1093
2024 Q1	$43.2K	Buy	243 +234	+2,600%	+$32.5K	﹤0.01%	1172
2023 Q4	$1.12K	Hold	9	–	–	﹤0.01%	2201
2023 Q3	$1.04K	Hold	9	–	–	﹤0.01%	2200
2023 Q2	$1.06K	Buy	+9	New	+$919	﹤0.01%	2160

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Huntington National Bank's KRYS Position: Q1 2026 in Review

Huntington National Bank reduced its Krystal Biotech (KRYS) stake by 2.7% in Q1 2026, selling an estimated $1.33K and leaving 183 shares worth $47.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Huntington National Bank first reported a position in KRYS in Q2 2023 and has held it in 12 quarters since. The position peaked at $104K in Q3 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

Huntington National Bank held 183 shares of Krystal Biotech worth $47.3K as of Q1 2026.
Huntington National Bank sold 5 Krystal Biotech shares in Q1 2026, an estimated $1.33K.
Krystal Biotech made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1359 holding.
Huntington National Bank first reported a position in Krystal Biotech in Q2 2023 and has held it in 12 quarters since.
Huntington National Bank's Krystal Biotech position peaked at $104K in Q3 2024.
367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.